SMN-C3 Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

416.52

DMSO: 5mg/mL (12.00mM) Need ultrasonic
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)

C24H28N6O

O=C1C=C(C2=NN3C(C(C)=NC(C)=C3)=C2)N=C4N1C=C(C5CCN(CC)CC5)C=C4C

1449597-34-5

SMN

At P16, the vehicle-treated D7 mice were much smaller than the control group of heterozygous litter pups and were dying. In contrast, D7 mice treated with high doses of SMN-C3 showed a phenotype similar to the heterozygous control. In the D7 mice, SMN-C3 treatment,induces a dose-dependent bodyweight gain, with some animals showing a body weight that is ~80% that of heterozygous controls. SMN-C3 normalizes the motor behavior of D7 mice, illustrated by the ability of the mice to right themselves as quickly as heterozygous controls and by their level of locomotor activity. Most importantly, whereas vehicle-treated mice die within 3 weeks after birth with a median survival of 18 days, SMN-C3 treatment,increases survival in a dose-dependent manner to a median survival time of 28 days in the low-dose (0.3mg/kg per day) group. In the two higher-dose groups (1 and 3mg/kg per day), ~90% of animals survive beyond P65 when the study is completed.